Abstract
Methods A cohort study of 57 PID patients was reviewed 3 months post-transition to the 20% Subcutaneous Immunoglobulin (HizentraTM), in order to evaluate clinical outcomes and adverse events related to a dose-equivalent switch from 10% liquid solution intravenous (Privigen and Gamunex) or 16% subcutaneous replacement therapy (Vivaglobin) to weekly infusion of HizentraTM, Descriptive analyses were performed in relations to IgG levels, total infusion volume and infusion time.
Highlights
A cohort study of 57 primary immunodeficiency disorders (PID) patients was reviewed 3 months post-transition to the 20% Subcutaneous Immunoglobulin (HizentraTM), in order to evaluate clinical outcomes and adverse events related to a dose-equivalent switch from 10% liquid solution intravenous (Privigen® and Gamunex®) or 16% subcutaneous replacement therapy (Vivaglobin®) to weekly infusion of HizentraTM, Descriptive analyses were performed in relations to IgG levels, total infusion volume and infusion time
The study showed IgG levels achieved with HizentraTM, were similar to pre-study levels with subcutaneous and higher by 17.1% compared to intravenous IgG
Lower infusion volume with HizentraTM, led to a reduction in total infusion time and in the number of infusion sites compared to other subcutaneous replacement therapy
Summary
Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (HizentraTM), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients. From Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting 2012 Calgary, Canada. From Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting 2012 Calgary, Canada. 11-14 October 2012
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
